Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Medicinova (MNOV) Return on Sales (2021 - 2025)

Medicinova (MNOV) has disclosed Return on Sales for 7 consecutive years, with 47.95% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales changed N/A to 47.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.38%, a N/A change, with the full-year FY2025 number at 0.02%, changed N/A from a year prior.
  • Return on Sales was 47.95% for Q4 2025 at Medicinova, up from 27.42% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 47.95% in Q4 2025 to a low of 95.09% in Q3 2021.
  • A 5-year average of 8.38% and a median of 3.0% in 2022 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was -184bps in 2022; the steepest drop was -296bps in 2022.
  • Medicinova's Return on Sales stood at 0.77% in 2021, then plummeted by -491bps to 3.0% in 2022, then tumbled by -135bps to 7.05% in 2023, then surged by 36bps to 4.49% in 2024, then surged by 1169bps to 47.95% in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Return on Sales are 47.95% (Q4 2025), 27.42% (Q3 2025), and 4.49% (Q2 2024).